Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FTC's Merger Concerns Remain Despite Amgen’s ‘Bare Commitment’ Not To Bundle Horizon Drugs

Executive Summary

The commission seeks a preliminary injunction by 31 October to block the closing of the proposed Amgen-Horizon merger. Harvard Professor Aaron Kesselheim, FTC’s expert, says Amgen could circumvent a commitment not to bundle its and Horizon's products. The Pfizer-Seagen merger agreement also gets a second request for information.

You may also be interested in...



FTC’s Test Case Opposing Amgen-Horizon Deal Ends With No-Bundling Agreement

Commission pursued merger challenge to halt pharma practices it believes can stifle competition and keep drug prices high. Other large biopharma transactions may face similar challenges as FTC pursues its new merger program.

FTC Is Ready To Negotiate Over Amgen/Horizon Merger

Amgen asked the FTC to accept its pledge not to bundle Horizon’s Tepezza or Krystexxa, while an FTC administrative law judge urged a settlement between the agency and Amgen.

FTC Is Ready To Negotiate Over Amgen/Horizon Merger

Amgen asked the FTC to accept its pledge not to bundle Horizon’s Tepezza or Krystexxa, while an FTC administrative law judge urged a settlement between the agency and Amgen.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS148555

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel